1344 recruiting. 1344 Phase 2, 319 Phase 1, 85 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1344 | Recruiting 1344 |
| Phase 1 | 319 | Recruiting 319 |
| Phase 3 | 85 | Recruiting 85 |
Follow Digestive System Diseases: new trials by email Literature Review of Digestive System Diseases trials Research Report on Digestive System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 31 | 2027-06-01 | 2026-10-22 |
| Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial Balstilimab, Biopsy Procedure, Biospecimen Collection - Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2027-05-25 | 2026-09-29 |
| ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer ANO31905, AG [gemcitabine+nab-paclitaxel], mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil] - Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Anova Innovation Limited | 84 | 2026-12-01 | 2026-10-23 |
| Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates High Rare Dose Rectal Brachytherapy Boost - Rectal Adenocarcinoma, Rectal Cancer | Phase 2 | Recruiting | University of Colorado, Denver | 44 | 2026-11-01 | 2026-09-02 |
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation Aquamin - Ulcerative Colitis, Ileal Pouch | Phase 2 | Recruiting | Muhammad N Aslam, MD | 52 | 2026-11-01 | 2026-11-02 |
| Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors ETX-929 dose escalation, ETX-929 dose escalation in combination with cetuximab - Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 / Phase 2 | Recruiting | Ensem Therapeutics | 320 | 2026-10-22 | 2026-11-03 |
| CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors CR-002 - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ | Phase 1 / Phase 2 | Recruiting | Crescent Biopharma, Inc. | 219 | 2026-10-21 | 2026-11-02 |
| A Study of SL-325 in Crohn's Disease Patients SL-325, Placebo - Crohn's Disease | Phase 2 | Recruiting | Shattuck Labs, Inc. | 232 | 2026-10-21 | 2026-11-03 |
| A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer Minocycline, Hypochlorous Acid, Hydrocortison cream - Pancreatic Cancer, Skin Toxicities | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 122 | 2026-10-16 | 2026-10-26 |
| An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors HRS-7172 + AG + SHR-1316, HRS-7172 + AG + SHR-1316;, HRS-7172 + AG; - Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 140 | 2026-10-15 | 2026-10-26 |
| Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer Becotatug Vedotin (MRG003), Pucotenlimab - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Fudan University | 31 | 2026-10-15 | 2026-10-20 |
| PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy - Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | Samsung Medical Center | 38 | 2026-10-15 | 2026-10-21 |
| A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma) anlotinib + PD-1 inhibitor, PD-1 inhibitor - Esophageal Cancer (EC) | Phase 2 | Recruiting | Sun Yat-sen University | 112 | 2026-10-12 | 2026-10-07 |
| Phase II Study of Primary Tumor Resection and Selective Lymph Node Dissection Followed by RT for BTC With Lymph Node Metastases Primary Tumor Resection and Selective Lymph Node Dissection, Postoperative Radiotherapy, Capecitabine or S-1 - Biliary Tract Cancer (BTC), Surgery | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 73 | 2026-10-08 | 2026-10-26 |
| A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted Immunochemotherapy Trastuzumab + Durvalumab + FLOT - Gastric Cancer | Phase 2 | Recruiting | Samsung Medical Center | 20 | 2026-10-06 | 2026-11-02 |
| Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction Fosamprenavir Calcium, Placebo - Laryngopharyngeal Reflux | Phase 2 | Recruiting | Medical College of Wisconsin | 104 | 2026-10-01 | 2026-09-10 |
| Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Iparomlimab and Tuvonralimab (QL1706), Lenvatinib, Radiotherapy - HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 35 | 2026-10-01 | 2026-09-15 |
| Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) - Colorectal Cancer, Gastric Cancers | Phase 2 / Phase 3 | Recruiting | GE Healthcare | 175 | 2026-10-01 | 2026-06-17 |
| A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency. NHS7108, Zenpep® - Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF) | Phase 2 | Recruiting | Aimmune Nestlé Health Science US R&D, LLC | 66 | 2026-10-01 | 2026-10-01 |
Showing 20 of 1344. Sign in to see all of them.
Colorectal Neoplasms (275) · Carcinoma, Hepatocellular (194) · Pancreatic Neoplasms (178) · Stomach Neoplasms (158) · Esophageal Neoplasms (97) · Esophageal Squamous Cell Carcinoma (81) · Rectal Neoplasms (81) · Carcinoma, Non-Small-Cell Lung (71) · Colonic Neoplasms (61) · Biliary Tract Neoplasms (60) · Neoplasm Metastasis (56) · Ovarian Neoplasms (55) · Lung Neoplasms (51) · Colitis, Ulcerative (50) · Neoplasms (48)
Digestive System Neoplasms (1047) · Neoplasms by Site (1036) · Neoplasms (1017) · Gastrointestinal Diseases (841) · Gastrointestinal Neoplasms (647) · Intestinal Diseases (523) · Neoplasms by Histologic Type (418) · Intestinal Neoplasms (396) · Colonic Diseases (390) · Neoplasms, Glandular and Epithelial (383) · Rectal Diseases (356) · Carcinoma (347) · Liver Diseases (293) · Adenocarcinoma (250)
Oxaliplatin (94) · Bevacizumab (79) · Fluorouracil (69) · Capecitabine (61) · Gemcitabine (60) · pembrolizumab (56) · Leucovorin (50) · sintilimab (46) · Cisplatin (44) · Drug Therapy (43) · Radiotherapy (41) · 130-nm albumin-bound paclitaxel (36) · tislelizumab (36) · Irinotecan (35) · durvalumab (35)
Fudan University (36) · Sun Yat-sen University (31) · Tianjin Medical University Cancer Institute and Hospital (19) · National Cancer Institute (NCI) (18) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (16) · M.D. Anderson Cancer Center (13) · Ruijin Hospital (13) · Peking Union Medical College Hospital (12) · Second Affiliated Hospital of Guangzhou Medical University (12) · The First Affiliated Hospital with Nanjing Medical University (12) · Asan Medical Center (11) · Mayo Clinic (11) · Second Affiliated Hospital, Zhejiang University, School of Medicine (11) · AstraZeneca (10) · Memorial Sloan Kettering Cancer Center (10)
China (602) · United States (481) · France (98) · South Korea (95) · Spain (87) · Italy (86) · Canada (85) · United Kingdom (79) · Germany (75) · Australia (72) · Taiwan (68) · Japan (67) · Netherlands (48) · Poland (43) · Belgium (39)
Zhenfeng Zhang, MD, PhD (5) · Filippo Pietrantonio, MD (4) · Hong Ren, MM (4) · Jinbo Yue, Doctor (4) · Matthew Krebs, Dr (4) · Eric Christenson, MD (3) · Jin Woo Choi, MD, PhD (3)
PMID 29366520, PMID 34143971, PMID 34606846, PMID 36529152, PMID 40056080, PMID 40812353, PMID 11171826, PMID 12229948, PMID 12907905, PMID 15057287, PMID 15234753, PMID 15383798, PMID 15496622, PMID 15623449, PMID 15740535, PMID 15868235, PMID 15868260, PMID 16177017, PMID 16400513, PMID 16552809, PMID 16813588, PMID 16966752, PMID 16971718, PMID 16983741, PMID 17008704, PMID 17175450, PMID 17252293, PMID 17252297, PMID 17968156, PMID 18452860, PMID 18468541, PMID 18844269, PMID 19058754, PMID 19097774, PMID 19212170, PMID 19269519, PMID 20060381, PMID 20395841, PMID 20632311, PMID 20692872, PMID 20728210, PMID 20842054, PMID 21178866, PMID 21561347, PMID 21596621, PMID 21831177, PMID 22067400, PMID 22228948, PMID 22539154, PMID 22658128
2025 (43), 2023 (30), P30CA033572 (4), P30CA060553 (4), 2017 (3), P30CA138292 (3), UM1CA186689 (3), P30CA046592 (2), UG1CA242632 (2), 2016 (1), 2018 (1), 2019 (1), 5UH3NS115108-04 (1), I01CX002349 (1), I01CX002436 (1)